189330 — XIIlab Co Balance Sheet
0.000.00%
- KR₩60bn
- KR₩50bn
- KR₩4bn
Annual balance sheet for XIIlab Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1,637 | 3,228 | 25,042 | 18,945 | 13,150 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2,082 | 5,608 | 1,010 | 5,339 | 910 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 3,808 | 8,852 | 26,076 | 24,291 | 14,080 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2,311 | 2,236 | 4,341 | 3,531 | 2,308 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 6,338 | 11,861 | 31,358 | 28,800 | 18,017 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3,353 | 7,582 | 3,816 | 5,903 | 1,447 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 4,782 | 8,743 | 6,829 | 8,071 | 3,202 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 1,556 | 3,118 | 24,529 | 20,729 | 14,814 |
Total Liabilities & Shareholders' Equity | 6,338 | 11,861 | 31,358 | 28,800 | 18,017 |
Total Common Shares Outstanding |